- Home
- MNPR
as 11-15-2024 4:00pm EST
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WILMETTE |
| Market Cap: | 95.5M | IPO Year: | 2019 |
| Target Price: | $27.33 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.37 - $38.50 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Monopar Therapeutics Inc. (MNPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Radhakrishnan Karthik | MNPR | Chief Financial Officer | Oct 28 '24 | Buy | $16.25 | 1,550 | $25,187.50 | 1,550 |
Latest Monopar Therapeutics Inc. News
MNPR Breaking Stock News: Dive into MNPR Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
MT Newswires
18 days ago
Monopar Therapeutics Closes $19.2 Million Common Stock Offering
GlobeNewswire
18 days ago
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
MT Newswires
20 days ago
Monopar Therapeutics Prices Best Efforts Public Offering at $16.25 per Share
GlobeNewswire
20 days ago
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
GlobeNewswire
20 days ago
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
Simply Wall St.
22 days ago
Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week
TipRanks
23 days ago
Monopar Therapeutics Secures License for Wilson Disease Treatment
Compare MNPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNPR Monopar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.